- Home
- REGN vs MRVL Comparison
REGN vs MRVL Comparison
Compare REGN & MRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- MRVL
- Stock Information
- Founded
- REGN 1988
- MRVL 1995
- Country
- REGN United States
- MRVL United States
- Employees
- REGN N/A
- MRVL N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- MRVL Semiconductors
- Sector
- REGN Health Care
- MRVL Technology
- Exchange
- REGN Nasdaq
- MRVL Nasdaq
- Market Cap
- REGN 59.5B
- MRVL 65.7B
- IPO Year
- REGN 1991
- MRVL 2000
- Fundamental
- Price
- REGN $589.48
- MRVL $73.00
- Analyst Decision
- REGN Buy
- MRVL Strong Buy
- Analyst Count
- REGN 22
- MRVL 30
- Target Price
- REGN $806.32
- MRVL $100.03
- AVG Volume (30 Days)
- REGN 1.0M
- MRVL 16.1M
- Earning Date
- REGN 08-01-2025
- MRVL 08-28-2025
- Dividend Yield
- REGN 0.60%
- MRVL 0.33%
- EPS Growth
- REGN 5.03
- MRVL N/A
- EPS
- REGN 39.67
- MRVL N/A
- Revenue
- REGN $14,214,200,000.00
- MRVL $6,501,700,000.00
- Revenue This Year
- REGN N/A
- MRVL $45.84
- Revenue Next Year
- REGN $6.65
- MRVL $17.93
- P/E Ratio
- REGN $14.86
- MRVL N/A
- Revenue Growth
- REGN 5.38
- MRVL 21.60
- 52 Week Low
- REGN $476.49
- MRVL $47.09
- 52 Week High
- REGN $1,211.20
- MRVL $127.48
- Technical
- Relative Strength Index (RSI)
- REGN 60.67
- MRVL 45.42
- Support Level
- REGN $570.39
- MRVL $68.54
- Resistance Level
- REGN $585.00
- MRVL $80.06
- Average True Range (ATR)
- REGN 16.72
- MRVL 2.83
- MACD
- REGN 2.93
- MRVL -0.84
- Stochastic Oscillator
- REGN 68.39
- MRVL 38.72
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.